Аналоги (1 поколение)
Аналоги (новое поколение)
Нуклеозидные аналоги, замещённые по 5-положению 1,2,4- триазольного кольца, и их активность против НCV,
измеренная на репликоне вируса в клеточной линии Huh-6
Аналоги (анти-TMV)
Аналоги (анти-HCV)
Аналоги (противораковые)
Xia Y., Wang M., Beraldi E., Cong M., Zoubeidi A., Gleave M., Peng L. A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor // Anticancer Agents Med Chem. 2015. V. 15, № 10. P. 1333-40.
SAR
(A)LNCaP cells were cultured for 48 hours in the presence of VM1 and enzalutamide at the indicated concentration with DMSO as vehicle control. (B) Antiproliferation activity of compound VM1-VM7 in LNCaP cells at 25 µM. (C) IC50 of
VM1 in different prostate cancer cell lines. (D) Significant increase of caspase-3/7 activity following the treatment of VM1 was determined by the cleavage of the luminogenic substrate containing the tetrapeptide sequence DEVD inLNCaP cells.
Heat shock factor 1 and heat shock proteins in the regulation of apoptosis and proliferation.
F3C |
|
|
|
N |
CONH2 |
|
|
|
HO |
N N |
|
|
|
|
Cl |
|
|
N |
HO |
|
O |
N |
N |
|
N N |
N |
HO |
|
|
H |
|
O |
|
|
N N |
|
|
|
HO |
|
|
|
|
|
|
|
|
|
CF3 |
|
|
|
|
|
|
O |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
OH |
OH |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
N |
|
|
CONH2 |
|
|
|
|
|
OH |
OH |
|||
|
|
|
|
|
|
|
|
|
|
|
|
11 |
|
|
12 |
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
HO |
|
N |
|
N |
|
|
|
|
||||||||||||||
|
|
|
|
|
|
McDowell M., Gonzales S. R., |
||||||||||||||||
|
|
|
|
|
|
|||||||||||||||||
|
|
|
|
O |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kumarapperuma S. C., Jeselnik |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
OH |
|
OH |
|
|
|
|
|
|
|
|
|
|
M., Arterburn J. B., Hanley K. |
||||||
|
|
|
|
29b |
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
R |
|
A. A novel nucleoside analog, |
|||||||||
|
|
|
|
|
|
|
|
|
|
|
N |
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
N |
|
1-beta-d-ribofuranosyl-3- |
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
14 a-d : X=OH |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ethynyl-[1,2,4]triazole (ETAR), |
|||||
|
|
|
|
|
|
|
|
|
|
|
N N |
|
|
|
|
|||||||
HO |
|
|
|
|
|
|
|
|
|
|
|
15 a-d : X= H |
|
exhibits efficacy against a |
||||||||
|
|
|
|
|
O |
|
|
|
|
|
|
|
|
|
broad range of flaviviruses in |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
R= H (a); Me (b); i-Pr (c); Ph (d) |
|
vitro // Antiviral Res. 2010. V. |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
87, № 1. P. 78-80. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
OH |
|
X |
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
Liu W. Y., Li H. Y., Zhao B. X., |
|||||||||||||
Zhurilo N. I., Chudinov M. V., Matveev A. V., |
|
|||||||||||||||||||||
|
Shin D. S., Lian S., Miao J. Y. |
|||||||||||||||||||||
Smirnova O. S., Konstantinova I. D., Miroshnikov A.Synthesis of novel ribavirin |
||||||||||||||||||||||
I., Prutkov A. N., Grebenkina L. E., Pulkova N. V., |
|
hydrazone derivatives and |
||||||||||||||||||||
Shvets V. I. Isosteric ribavirin analogues: Synthesisanti-proliferative activity |
||||||||||||||||||||||
and antiviral activities // Bioorganic & Medicinal |
|
against A549 lung cancer cells |
||||||||||||||||||||